Home Healthcare IT South Korea Autoinjectors Market Share, Growth to 2033

South Korea Autoinjectors Market Size, Share & Trends Analysis Report By Type (Disposable autoinjectors, Reusable autoinjectors), By Application (Rheumatoid arthritis, Anaphylaxis, Multiple sclerosis, Others), By End-User (Home Care Settings, Hospitals and Clinics) and Forecasts, 2025-2033

Report Code: SRHI7822DR
Last Updated: Jun, 2023
Pages: 80
Author: Debashree Bora
Format: PDF, Excel

Market Overview

The South Korea Autoinjectors Market size was valued at USD 184.37 Million in 2024 and is projected to grow from USD 222.16 Million in 2025 to reach USD 987.56 Million by 2033, growing at a CAGR of 20.5% during the forecast period (2025–2033). 

Highlights

  • Anaphylaxis dominates the market by therapy.
  • Disposable dominates the market by type.
  • Homecare dominates the market by end-user.

An autoinjector is a medical tool used to administer a specified amount of medication, usually by injection. It usually consists of a pre-filled syringe, a needle, and a spring-loaded mechanism that administers the drug fast and easily with the push of a button. It is made to be simple to use by the patient or caregiver. Autoinjectors are frequently used to treat Allergies, rheumatoid arthritis, and multiple sclerosis. They can help lower the risk of unintentional needle stick injuries and are frequently utilized in emergency settings where quick medicine administration is required.

Market Summary

Market Metric Details & Data (2024-2033)
2024 Market Valuation USD 184.37 Million
Estimated 2025 Value USD 222.16 Million
Projected 2033 Value USD 987.56 Million
CAGR (2025-2033) 20.5%
Key Market Players Pfizer Inc. (Meridian Medical Technologies, Inc.), AbbVie Inc., Sanofi, SHL Group, Becton, Dickinson, and Company
South Korea Autoinjectors Market Size

to learn more about this report Download Free Sample Report

Market Dynamics

South Korea Autoinjectors Market Drivers

Pressing Need for Patients' Convenience

A large portion of South Korea's population is getting older, which has raised the prevalence of chronic illnesses like rheumatoid arthritis. Disease-modifying antirheumatic medications (DMARDs) are frequently injected into rheumatoid arthritis patients daily to treat their illness. Autoinjectors provide a practical and simple way for patients to self-administer these injections at home, allowing them to continue their treatment without frequent trips to medical institutions. Easy and simple medication administration enhances patient compliance and treatment outcomes overall. Because of this, autoinjectors offer a practical solution for administering insulin, enabling patients to do so comfortably, even in public places. Autoinjectors allow individuals to conveniently deliver their insulin dosages without needing elaborate preparation or assistance from healthcare experts due to their small size, straightforward operation, and discrete design.

South Korea Autoinjectors Market Restraints

Increasing Preference for Alternative Drug Delivery Modes

The rising preference for alternate drug delivery methods, such as oral pharmaceuticals or wearable gadgets, may constrain the market expansion of autoinjectors in South Korea. Due to convenience, patient preference, and the availability of alternative treatment options, patients and healthcare practitioners may choose to use these alternative approaches. The creation and use of innovative oral drugs to treat chronic illnesses have become increasingly popular in South Korea. For instance, oral disease-modifying antirheumatic medicines (DMARDs) offer a viable option for injections in treating rheumatoid arthritis. With less need for repeated injections and less reliance on autoinjectors, these oral drugs provide convenience and ease of administration. Some patient demographics' preference for oral drugs may restrain the market expansion of autoinjectors.

South Korea Autoinjectors Market Opportunities

Growing Demand for Biologics and Biosimilars

Biologic therapy is used more frequently in South Korea to treat rheumatoid arthritis, inflammatory bowel disease, and psoriasis. These biologics must be delivered precisely, and patients frequently self-administer them using autoinjectors. For instance, autoinjectors can be used by rheumatoid arthritis patients to deliver drugs like adalimumab or etanercept at home conveniently and more effectively. According to the Korea Biomedical Review, the South Korean biosimilar market has expanded significantly. The South Korean biosimilar market grew by 22.4% annually from 2019 to 2020, reaching KRW 3.15 trillion (about USD 2.8 billion). Increased usage of autoinjectors as the preferred method of administration, cost-effectiveness, and increased patient access to biologic medicines are some factors driving demand for biosimilars. Using autoinjectors with the rising demand for biologics and biosimilars creates a sizable opportunity for the South Korea autoinjector industry.

Regional Analysis

The South Korean autoinjector revenue has expanded significantly in recent years. Self-administration of pharmaceuticals has become more important as the prevalence of chronic diseases like rheumatoid arthritis, diabetes, and multiple sclerosis has increased in South Korea. Patients can easily and effectively give their prescribed medicines with the help of autoinjectors. According to the International Diabetes Federation, 4.8 million adults in South Korea had diabetes in 2019. This is around 9.6% of the adult population. The Korean Ministry of Food and Drug Safety has also authorized using many biosimilars nationwide, including those used to treat cancer, inflammatory bowel disease, and rheumatoid arthritis. The Korean Society for Quality in Healthcare has been advancing patient-centered care models, encouraging patient participation in treatment regimens, and supporting instruments like autoinjectors to facilitate self-administration.

Segmental Analysis

The South Korea autoinjectors market is segmented based on therapy, type, end-user, and country.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 20.8% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 21.2% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 21.2% during the forecast period.

List of Key and Emerging Players in South Korea Autoinjectors Market

  1. Pfizer Inc. (Meridian Medical Technologies, Inc.)
  2. AbbVie Inc.
  3. Sanofi
  4. SHL Group
  5. Becton, Dickinson, and Company
  6. Biogen
  7. Novartis AG
  8. Antares Pharma

Recent Developments

  • May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.
  • April 2023- Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") selected the target AVERSATM formulation for commercial scale manufacturing process development for the Company's patented lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system.

Report Scope

Report Metric Details
Market Size in 2024 USD 184.37 Million
Market Size in 2025 USD 222.16 Million
Market Size in 2033 USD 987.56 Million
CAGR 20.5% (2025-2033)
Base Year for Estimation 2024
Historical Data2021-2023
Forecast Period2025-2033
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered By Product Type, By Indication

to learn more about this report Download Free Sample Report

South Korea Autoinjectors Market Segments

By Product Type

  • Disposable
  • Reusable

By Indication

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis

Frequently Asked Questions (FAQs)

What is the growth rate for the South Korea autoinjectors market?
The South Korea market growing at a CAGR of 20.5% from (2025–2033).
The key players in the South Korea market include Pfizer Inc, AbbVie Inc., Sanofi, SHL Group, Biogen, Novartis AG, and Antares Pharma.
The homecare segment is the leading segment for the market during the forecast period.
TPressing the need for patient convenience is the key driver supporting the growth of the South Korea market.

Debashree Bora

Healthcare Lead


Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.

Request Sample Order Report Now

We are featured on:

WhatsApp
Chat with us on WhatsApp